These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38216149)

  • 41. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis.
    Verheijden GF; Rijnders AW; Bos E; Coenen-de Roo CJ; van Staveren CJ; Miltenburg AM; Meijerink JH; Elewaut D; de Keyser F; Veys E; Boots AM
    Arthritis Rheum; 1997 Jun; 40(6):1115-25. PubMed ID: 9182922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy.
    Nanjaiah H; Moudgil KD
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.
    Isaacs JD
    Rheumatology (Oxford); 2008 Oct; 47(10):1461-8. PubMed ID: 18503092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospects of immunotherapy for rheumatoid arthritis.
    t Hart BA; Otten HG
    Pharm World Sci; 1995 Nov; 17(6):178-85. PubMed ID: 8597773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives.
    Zhao Y; Zhang A; Du H; Guo S; Ning B; Yang S
    Rheumatol Int; 2012 Apr; 32(4):837-44. PubMed ID: 21904923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural human antibodies to synthetic peptide autoantigens: correlations with age and autoimmune disease.
    Marchalonis JJ; Schluter SF; Wilson L; Yocum DE; Boyer JT; Kay MM
    Gerontology; 1993; 39(2):65-79. PubMed ID: 8514202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells.
    Yang J; Yang Y; Ren Y; Xie R; Zou H; Fan H
    PLoS One; 2013; 8(10):e77729. PubMed ID: 24204938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices?
    Kinne RW; Palombo-Kinne E; Emmrich F
    Biochim Biophys Acta; 1997 Apr; 1360(2):109-41. PubMed ID: 9128178
    [No Abstract]   [Full Text] [Related]  

  • 49. Insights of rheumatoid arthritis biomarkers.
    Kolarz B; Podgorska D; Podgorski R
    Biomarkers; 2021 May; 26(3):185-195. PubMed ID: 32662676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies.
    VanderBorght A; Geusens P; Raus J; Stinissen P
    Semin Arthritis Rheum; 2001 Dec; 31(3):160-75. PubMed ID: 11740797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral tolerance and the treatment of rheumatoid arthritis.
    Weiner HL; Komagata Y
    Springer Semin Immunopathol; 1998; 20(1-2):289-308. PubMed ID: 9836383
    [No Abstract]   [Full Text] [Related]  

  • 52. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells.
    Zhang B; Wang Y; Yuan Y; Sun J; Liu L; Huang D; Hu J; Wang M; Li S; Song W; Chen H; Zhou D; Zhang X
    Ann Rheum Dis; 2021 Feb; 80(2):176-184. PubMed ID: 32998865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.
    Chorny A; Gonzalez-Rey E; Fernandez-Martin A; Pozo D; Ganea D; Delgado M
    Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13562-7. PubMed ID: 16150720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. It feels like lupus: accessible science for the low-vision community on immune system dysfunction in lupus.
    Bennett TJ
    Immunol Cell Biol; 2024; 102(5):347-352. PubMed ID: 38497354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis?
    Thomas R; Lipsky PE
    Immunol Today; 1996 Dec; 17(12):559-64. PubMed ID: 8991287
    [No Abstract]   [Full Text] [Related]  

  • 56. Vitamin D Deficiency and Rheumatoid Arthritis.
    Ishikawa LLW; Colavite PM; Fraga-Silva TFC; Mimura LAN; França TGD; Zorzella-Pezavento SFG; Chiuso-Minicucci F; Marcolino LD; Penitenti M; Ikoma MRV; Sartori A
    Clin Rev Allergy Immunol; 2017 Jun; 52(3):373-388. PubMed ID: 27484684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.
    Moorman CD; Sohn SJ; Phee H
    Front Immunol; 2021; 12():657768. PubMed ID: 33854514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment.
    Sakkas LI; Bogdanos DP; Katsiari C; Platsoucas CD
    Autoimmun Rev; 2014 Nov; 13(11):1114-20. PubMed ID: 25182207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matured Tolerogenic Dendritic Cells Effectively Inhibit Autoantigen Specific CD4
    Jansen MAA; Spiering R; Ludwig IS; van Eden W; Hilkens CMU; Broere F
    Front Immunol; 2019; 10():2068. PubMed ID: 31555285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis.
    Zhu P; Li XY; Wang HK; Jia JF; Zheng ZH; Ding J; Fan CM
    Clin Immunol; 2007 Jan; 122(1):75-84. PubMed ID: 17045846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.